. Referanser

Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., & Bartlett, N. L. (2014). Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. Journal of clinical oncology, 32(9), 912-918. https://doi.org/10.1200/JCO.2013.53.2069

Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. O., Berti, E., . . . Xiao, W. (2022). The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 36(7), 1720-1748. https://doi.org/10.1038/s41375-022-01620-2

Aleman, B. M., Raemaekers, J. M., Tirelli, U., Bortolus, R., van 't Veer, M. B., Lybeert, M. L., . . . Treatment of Cancer Lymphoma Group. (2003). Involved-field radiotherapy for advanced Hodgkin's lymphoma. The New England journal of medicine, 348(24), 2396-2406. https://doi.org/10.1056/NEJMoa022628

Anderlini, P., Saliba, R., Acholonu, S., Giralt, S. A., Andersson, B., Ueno, N. T., . . . Champlin, R. E. (2008). Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica, 93(2), 257-264. https://doi.org/10.3324/haematol.11828

Anderson, R. A., Remedios, R., Kirkwood, A. A., Patrick, P., Stevens, L., Clifton-Hadley, L., . . . Johnson, P. W. M. (2018). Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. The Lancet. Oncology, 19(10), 1328-1337. https://doi.org/10.1016/s1470-2045(18)30500-x

Andre, M. P. E., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., . . . Raemaekers, J. (2017). Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. Journal of clinical oncology, 35(16), 1786-1794. https://doi.org/10.1200/JCO.2016.68.6394

Ansell, S. M., Radford, J., Connors, J. M., Długosz-Danecka, M., Kim, W. S., Gallamini, A., . . . Straus, D. J. (2022). Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. The New England journal of medicine, 387(4), 310-320. https://doi.org/10.1056/NEJMoa2206125

Ardeshna, K. M., Qian, W., Smith, P., Braganca, N., Lowry, L., Patrick, P., . . . Linch, D. C. (2014). Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. The Lancet. Oncology, 15(4), 424-435. https://doi.org/10.1016/S1470-2045(14)70027-0

Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Mueller, S. P., . . . Cheson, B. D. (2014). Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of clinical oncology, 32(27), 3048-3058. https://doi.org/10.1200/JCO.2013.53.5229

Barzenje, D. A., Holte, H., Fosså, A., Ghanima, W., Liestøl, K., Delabie, J., & Kolstad, A. (2017). Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. Leukemia & lymphoma, 58(3), 623-632. https://doi.org/10.1080/10428194.2016.1204653

Barzenje, D. A., Kolstad, A., Ghanima, W., & Holte, H. (2018). Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years. Hematological oncology, 36(1), 217-223. https://doi.org/10.1002/hon.2415

Bastings, L., Beerendonk, C. C., Westphal, J. R., Massuger, L. F., Kaal, S. E., van Leeuwen, F. E., . . . Peek, R. (2013). Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Human reproduction update, 19(5), 483-506. https://doi.org/10.1093/humupd/dmt020

Batchelor, T., & Loeffler, J. S. (2006). Primary CNS lymphoma. Journal of clinical oncology, 24(8), 1281-1288. https://doi.org/10.1200/JCO.2005.04.8819

Behringer, K., Mueller, H., Goergen, H., Thielen, I., Eibl, A. D., Stumpf, V., . . . Borchmann, P. (2013). Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of clinical oncology, 31(2), 231-239. https://doi.org/10.1200/jco.2012.44.3721

Behringer, K., Thielen, I., Mueller, H., Goergen, H., Eibl, A. D., Rosenbrock, J., . . . Borchmann, P. (2012). Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of oncology, 23(7), 1818-1825. https://doi.org/10.1093/annonc/mdr575

Behringer, K., Wildt, L., Mueller, H., Mattle, V., Ganitis, P., van den Hoonaard, B., . . . Borchmann, P. (2010). No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Annals of oncology, 21(10), 2052-2060. https://doi.org/10.1093/annonc/mdq066

Bennett, M., Sharma, K., Yegena, S., Gavish, I., Dave, H. P., & Schechter, G. P. (2005). Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica, 90(6), 856-858.

Bersvendsen, H., Kolstad, A., Blystad, A. K., Aurlien, E., Fosså, A., Kvaløy, S. O., . . . Lauritzsen, G. F. (2014). Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma. Acta oncologica, 53(5), 680-687. https://doi.org/10.3109/0284186X.2013.855816

Bertoni, F., & Zucca, E. (2005). State-of-the-art therapeutics: marginal-zone lymphoma. Journal of clinical oncology, 23(26), 6415-6420. https://doi.org/10.1200/JCO.2005.05.018

Blaker, Y. N., Eide, M. B., Liestøl, K., Lauritzsen, G. F., Kolstad, A., Fosså, A., . . . Holte, H. (2014). High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. Leukemia & lymphoma, 55(10), 2319-2327. https://doi.org/10.3109/10428194.2013.871632

Boeckh, M., & Ljungman, P. (2009). How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood, 113(23), 5711-5719. https://doi.org/10.1182/blood-2008-10-143560

Boehme, V., Zeynalova, S., Kloess, M., Loeffler, M., Kaiser, U., Pfreundschuh, M., . . . German High-Grade Non-Hodgkin's Lymphoma Study Group. (2007). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Annals of oncology, 18(1), 149-157. https://doi.org/10.1093/annonc/mdl327

Bonnet, C., Fillet, G., Mounier, N., Ganem, G., Molina, T. J., Thieblemont, C., . . . Groupe d'Etude des Lymphomes de l'Adulte. (2007). CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Journal of clinical oncology, 25(7), 787-792. https://doi.org/10.1200/JCO.2006.07.0722

Borchmann, P., Goergen, H., Kobe, C., Lohri, A., Greil, R., Eichenauer, D. A., . . . Engert, A. (2018). PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet, 390(10114), 2790-2802. https://doi.org/10.1016/S0140-6736(17)32134-7

Borchmann, P., Haverkamp, H., Lohri, A., Mey, U., Kreissl, S., Greil, R., . . . Engert, A. (2017). Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. The Lancet. Oncology, 18(4), 454-463. https://doi.org/10.1016/S1470-2045(17)30103-1

Borchmann, P., Plütschow, A., Kobe, C., Greil, R., Meissner, J., Topp, M. S., . . . Engert, A. (2021). PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology, 22(2), 223-234. https://doi.org/10.1016/S1470-2045(20)30601-X

Boue, F., Gabarre, J., Gisselbrecht, C., Reynes, J., Cheret, A., Bonnet, F., . . . Costagliola, D. (2006). Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. Journal of clinical oncology, 24(25), 4123-4128. https://doi.org/10.1200/JCO.2005.05.4684

Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haïoun, C., Moreau, P., . . . Solal-Céligny, P. (1997). Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Journal of clinical oncology, 15(3), 1110-1117. https://doi.org/10.1200/jco.1997.15.3.1110

Campo, E. (2015). MYC in DLBCL: partners matter. Blood, 126(22), 2439-2440. https://doi.org/10.1182/blood-2015-10-671362

Campo, E. (2017). Pathology and classification of aggressive mature B-cell lymphomas. Hematological oncology, 35 Suppl 1, 80-83. https://doi.org/10.1002/hon.2406

Campo, E., Jaffe, E. S., Cook, J. R., Quintanilla-Martinez, L., Swerdlow, S. H., Anderson, K. C., . . . Zelenetz, A. D. (2022). The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 140(11), 1229-1253. https://doi.org/10.1182/blood.2022015851

Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., . . . Peterson, B. A. (1992). Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. The New England journal of medicine, 327(21), 1478-1484. https://doi.org/10.1056/NEJM199211193272102

Carter, A., Robison, L. L., Francisco, L., Smith, D., Grant, M., Baker, K. S., . . . Bhatia, S. (2006). Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone marrow transplantation, 37(11), 1023-1029. https://doi.org/10.1038/sj.bmt.1705364

Casasnovas, R. O., Bouabdallah, R., Brice, P., Lazarovici, J., Ghesquieres, H., Stamatoullas, A., . . . Meignan, M. (2019). PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. The Lancet. Oncology, 20(2), 202-215. https://doi.org/10.1016/s1470-2045(18)30784-8

Casulo, C., & Barr, P. M. (2019). How I treat early-relapsing follicular lymphoma. Blood, 133(14), 1540-1547. https://doi.org/10.1182/blood-2018-08-822148

Cavalli, F., Isaacson, P. G., Gascoyne, R. D., & Zucca, E. (2001). MALT Lymphomas. Hematology. American Society of Hematology. Education Program, (1), 241-258. https://doi.org/10.1182/asheducation-2001.1.241

Chamberlain, M. C., Nolan, C., & Abrey, L. E. (2005). Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. Journal of neuro-oncology, 75(1), 71-83. https://doi.org/10.1007/s11060-004-8100-y

Cheah, C. Y., Wirth, A., & Seymour, J. F. (2014). Primary testicular lymphoma. Blood, 123(4), 486-493. https://doi.org/10.1182/blood-2013-10-530659

Cheson, B. D., Chua, N., Mayer, J., Dueck, G., Trněný, M., Bouabdallah, K., . . . Sehn, L. H. (2018). Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. Journal of clinical oncology, 36(22), 2259-2266. https://doi.org/10.1200/JCO.2017.76.3656

Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., . . . United Kingdom National Cancer Research Institute. (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. Journal of clinical oncology, 32(27), 3059-3068. https://doi.org/10.1200/JCO.2013.54.8800

Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., . . . Canellos, G. P. (1999). Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of clinical oncology, 17(4), 1244. https://doi.org/10.1200/JCO.1999.17.4.1244

Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., . . . International Harmonization Project on Lymphoma. (2007). Revised response criteria for malignant lymphoma. Journal of clinical oncology, 25(5), 579-586. https://doi.org/10.1200/JCO.2006.09.2403

Coiffier, B. (2006). Standard treatment of advanced-stage diffuse large B-cell lymphoma. Seminars in hematology, 43(4), 213-220. https://doi.org/10.1053/j.seminhematol.2006.07.004

Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., . . . Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England journal of medicine, 346(4), 235-242. https://doi.org/10.1056/NEJMoa011795

Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., . . . Echelon- Study Group. (2018). Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. The New England journal of medicine, 378(4), 331-344. https://doi.org/10.1056/NEJMoa1708984

Crump, M., Kuruvilla, J., Couban, S., MacDonald, D. A., Kukreti, V., Kouroukis, C. T., . . . Shepherd, L. E. (2014). Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. Journal of clinical oncology, 32(31), 3490-3496. https://doi.org/10.1200/JCO.2013.53.9593

Curt, G. A., Breitbart, W., Cella, D., Groopman, J. E., Horning, S. J., Itri, L. M., . . . Vogelzang, N. J. (2000). Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. The oncologist, 5(5), 353-360. https://doi.org/10.1634/theoncologist.5-5-353

Czuczman, M. S., Grillo-Lopez, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., . . . Varns, C. (1999). Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Journal of clinical oncology, 17(1), 268-276. https://doi.org/10.1200/JCO.1999.17.1.268

d'Amore, F., Relander, T., Lauritzsen, G. F., Jantunen, E., Hagberg, H., Anderson, H., . . . Toldbod, H. E. (2012). Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. Journal of clinical oncology, 30(25), 3093-3099. https://doi.org/10.1200/JCO.2011.40.2719

Dabaja, B. S., Ng, A. K., Terezakis, S. A., Plastaras, J. P., Yunes, M., Wilson, L. D., . . . Yahalom, J. (2020a). Making Every Single Gray Count: Involved Site Radiation Therapy Delineation Guidelines for Hematological Malignancies. International journal of radiation oncology, biology, physics, 106(2), 279-281. https://doi.org/10.1016/j.ijrobp.2019.10.029

Dabaja, B. S., Ng, A. K., Terezakis, S. A., Plastaras, J. P., Yunes, M., Wilson, L. D., . . . Yahalom, J. (2020b). ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma. International journal of radiation oncology, biology, physics, 108(4), 977-978. https://doi.org/10.1016/j.ijrobp.2020.05.063

Dahl, O., Lehne, G., & Christoffersen, T. (red.). (2016). Medikamentell kreftbehandling: cytostatikaboken (8. utg.). Oslo: Universitetet i Oslo, Avdeling for farmakologi.

Dean, R. M., Fowler, D. H., Wilson, W. H., Odom, J., Steinberg, S. M., Chow, C., . . . Bishop, M. R. (2005). Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. Biology of blood and marrow transplantation, 11(8), 593-599. https://doi.org/10.1016/j.bbmt.2005.04.005

Dearden, C. (2006). The role of alemtuzumab in the management of T-cell malignancies. Seminars in oncology, 33(2 Suppl 5), S44-52. https://doi.org/10.1053/j.seminoncol.2006.01.029

Delabie, J., Holte, H., Vose, J. M., Ullrich, F., Jaffe, E. S., Savage, K. J., . . . Weisenburger, D. D. (2011). Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood, 118(1), 148-155. https://doi.org/10.1182/blood-2011-02-335216

Demeestere, I., Brice, P., Peccatori, F. A., Kentos, A., Dupuis, J., Zachee, P., . . . Englert, Y. (2016). No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial. Journal of clinical oncology, 34(22), 2568-2574. https://doi.org/10.1200/jco.2015.65.8864

Diamond, C., Taylor, T. H., Im, T., Miradi, M., & Anton-Culver, H. (2006). Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy. Hematological oncology, 24(3), 139-145. https://doi.org/10.1002/hon.778

Dickinson, M., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G., . . . Hutchings, M. (2022). Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results. Journal of clinical oncology, 40(16_suppl), 7500-7500. https://doi.org/10.1200/JCO.2022.40.16_suppl.7500

Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., . . . German Hodgkin's Lymphoma Study Group. (2003). Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. The New England journal of medicine, 348(24), 2386-2395. https://doi.org/10.1056/NEJMoa022473

Diehl, V., Sextro, M., Franklin, J., Hansmann, M. L., Harris, N., Jaffe, E., . . . Stein, H. (1999). Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. Journal of clinical oncology, 17(3), 776-783. https://doi.org/10.1200/JCO.1999.17.3.776

Dimeo, F. C., Stieglitz, R. D., Novelli-Fischer, U., Fetscher, S., & Keul, J. (1999). Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer, 85(10), 2273-2277.

Dreger, P., Brand, R., Milligan, D., Corradini, P., Finke, J., Lambertenghi Deliliers, G., . . . Chronic Leukemia Working Party of the Ebmt. (2005). Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia, 19(6), 1029-1033. https://doi.org/10.1038/sj.leu.2403745

Dreyling, M., Jurczak, W., Jerkeman, M., Silva, R. S., Rusconi, C., Trneny, M., . . . Rule, S. (2016). Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet, 387(10020), 770-778. https://doi.org/10.1016/S0140-6736(15)00667-4

Dundee, J. W., Yang, J., & McMillan, C. (1991). Non-invasive stimulation of the P6 (Neiguan) antiemetic acupuncture point in cancer chemotherapy. Journal of the Royal Society of Medicine, 84(4), 210-212. https://doi.org/10.1177/014107689108400409

Duvic, M., Tetzlaff, M. T., Gangar, P., Clos, A. L., Sui, D., & Talpur, R. (2015). Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. Journal of clinical oncology, 33(32), 3759-3765. https://doi.org/10.1200/JCO.2014.60.3787

Eide, M. B., Lauritzsen, G. F., Kvalheim, G., Kolstad, A., Fagerli, U. M., Maisenhölder, M., . . . Holte, H. (2011). High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. British journal of haematology, 152(5), 600-610. https://doi.org/10.1111/j.1365-2141.2010.08519.x

Ekström-Smedby, K. (2006). Epidemiology and etiology of non-Hodgkin lymphoma--a review. Acta oncologica, 45(3), 258-271. https://doi.org/10.1080/02841860500531682

El-Galaly, T. C., Villa, D., Michaelsen, T. Y., Hutchings, M., Mikhaeel, N. G., Savage, K. J., . . . Cheah, C. Y. (2017). The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. European journal of cancer, 75, 195-203. https://doi.org/10.1016/j.ejca.2016.12.029

Elis, A., Blickstein, D., Klein, O., Eliav-Ronen, R., Manor, Y., & Lishner, M. (2002). Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies. American journal of hematology, 69(1), 41-44. https://doi.org/10.1002/ajh.10017

Engert, A., Ballova, V., Haverkamp, H., Pfistner, B., Josting, A., Duhmke, E., . . . German Hodgkin's Study Group. (2005). Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of clinical oncology, 23(22), 5052-5060. https://doi.org/10.1200/JCO.2005.11.080

Engert, A., Franklin, J., Eich, H. T., Brillant, C., Sehlen, S., Cartoni, C., . . . Diehl, V. (2007). Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Journal of clinical oncology, 25(23), 3495-3502. https://doi.org/10.1200/JCO.2006.07.0482

Engert, A., Plutschow, A., Eich, H. T., Lohri, A., Dorken, B., Borchmann, P., . . . Diehl, V. (2010). Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. The New England journal of medicine, 363(7), 640-652. https://doi.org/10.1056/NEJMoa1000067

Engert, A., Schiller, P., Josting, A., Herrmann, R., Koch, P., Sieber, M., . . . German Hodgkin's Lymphoma Study Group. (2003). Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Journal of clinical oncology, 21(19), 3601-3608. https://doi.org/10.1200/JCO.2003.03.023

Evens, A. M., Querfeld, C., & Rosen, S. T. (2006). T-cell non-Hogdkin's lymphoma. Cancer treatment and research, 131, 161-220.

Eyre, T. A., Djebbari, F., Kirkwood, A. A., & Collins, G. P. (2020). Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review. Haematologica, 105(7), 1914-1924. https://doi.org/10.3324/haematol.2019.229948

Ezzat, H., Filipenko, D., Vickars, L., Galbraith, P., Li, C., Murphy, K., . . . Leitch, H. A. (2007). Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy. HIV clinical trials, 8(3), 132-144. https://doi.org/10.1310/hct0803-132

Ezzo, J., Vickers, A., Richardson, M. A., Allen, C., Dibble, S. L., Issell, B., . . . Zhang, G. (2005). Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. Journal of clinical oncology, 23(28), 7188-7198. https://doi.org/10.1200/JCO.2005.06.028

Federico, M., Bellei, M., Marcheselli, L., Luminari, S., Lopez-Guillermo, A., Vitolo, U., . . . Solal-Celigny, P. (2009). Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. Journal of clinical oncology, 27(27), 4555-4562. https://doi.org/10.1200/JCO.2008.21.3991

Ferreri, A. J., Cwynarski, K., Pulczynski, E., Ponzoni, M., Deckert, M., Politi, L. S., . . . International Extranodal Lymphoma Study Group. (2016). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. The Lancet. Haematology, 3(5), e217-227. https://doi.org/10.1016/S2352-3026(16)00036-3

Ferreri, A. J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G. A., Frezzato, M., . . . International Extranodal Lymphoma Study Group. (2009). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, 374(9700), 1512-1520. https://doi.org/10.1016/S0140-6736(09)61416-1

Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., Celico, C., . . . Illerhaus, G. (2022). Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 36(7), 1870-1878. https://doi.org/10.1038/s41375-022-01582-5

Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosee, P., . . . International Extranodal Lymphoma Study Group. (2017). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. The Lancet. Haematology, 4(11), e510-e523. https://doi.org/10.1016/S2352-3026(17)30174-6

Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., . . . Miller, T. P. (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. The New England journal of medicine, 328(14), 1002-1006. https://doi.org/10.1056/NEJM199304083281404

Fløisand, Y., Brinch, L., Gedde-Dahl, T., Tjønnfjord, G. E., Dybedal, I., Holte, H., . . . Kolstad, A. (2012). Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. Bone marrow transplantation, 47(12), 1552-1557. https://doi.org/10.1038/bmt.2012.63

Foss Abrahamsen, A., Andersen, A., Nome, O., Jacobsen, A. B., Holte, H., Foss Abrahamsen, J., & Kvaløy, S. (2002). Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Annals of oncology, 13(11), 1786-1791. https://doi.org/10.1093/annonc/mdf289

Fosså, A., Fiskvik, I. H., Kolstad, A., Lauritzsen, G. F., Aurlien, E., Blystad, A. K., . . . Holte, H. (2012). Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis. Annals of oncology, 23(5), 1254-1259. https://doi.org/10.1093/annonc/mdr385

Fosså, A., Smeland, K., Fagerli, U. M., Galleberg, R. B., Bersvendsen, H. S., & Holte, H. (2020). Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016. Acta oncologica, 59(1), 101-105. https://doi.org/10.1080/0284186X.2019.1652765

Gang, A. O., Strøm, C., Pedersen, M., d'Amore, F., Pedersen, L. M., Bukh, A., . . . Nully Brown, P. d. (2012). R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Annals of oncology, 23(1), 147-153. https://doi.org/10.1093/annonc/mdr058

Garnock-Jones, K. P. (2013). Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs, 73(4), 371-381. https://doi.org/10.1007/s40265-013-0031-5

Gavrilovic, I. T., Hormigo, A., Yahalom, J., DeAngelis, L. M., & Abrey, L. E. (2006). Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. Journal of clinical oncology, 24(28), 4570-4574. https://doi.org/10.1200/JCO.2006.06.6910

Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., . . . Nordic Lymphoma Group. (2008). Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 112(7), 2687-2693. https://doi.org/10.1182/blood-2008-03-147025

Girbl, T., Lunzer, V., Greil, R., Namberger, K., & Hartmann, T. N. (2014). The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor. Transfusion, 54(9), 2325-2335. https://doi.org/10.1111/trf.12632

Gisselbrecht, C., Glass, B., Mounier, N., Gill, D. S., Linch, D. C., Trneny, M., . . . Schmitz, N. (2010). Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. Journal of clinical oncology, 28(27), 4184-4190. https://doi.org/10.1200/jco.2010.28.1618

Gjerstad, L., Skjeldal, O. H., & Helseth, H. (red.). (2003). Nevrologi og nevrokirurgi: fra barn til voksen: undersøkelse, diagnose, behandling (3. utg.). Nesbru: Vett & viten.

Glenny, A. M., Fernandez Mauleffinch, L. M., Pavitt, S., & Walsh, T. (2009). Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. The Cochrane database of systematic reviews, (1), CD006706. https://doi.org/10.1002/14651858.CD006706.pub2

Goldkuhl, C., Ekman, T., Wiklund, T., Telhaug, R., & Nordic Lymphoma Group. (2002). Age-adjusted chemotherapy for primary central-nervous system lymphoma--a pilot study. Acta oncologica, 41(1), 29-35. https://doi.org/10.1080/028418602317314037

Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., . . . Salles, G. A. (2014). PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. The New England journal of medicine, 370(11), 1008-1018. https://doi.org/10.1056/NEJMoa1314583

Gospodarowicz, M. Personlig meddelelse.

Guadagnolo, B. A., Punglia, R. S., Kuntz, K. M., Mauch, P. M., & Ng, A. K. (2006). Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. Journal of clinical oncology, 24(25), 4116-4122. https://doi.org/10.1200/JCO.2006.07.0409

Han, J. J., Kim, T. M., Jeon, Y. K., Kim, M. K., Khwarg, S. I., Kim, C. W., . . . Heo, D. S. (2015). Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. Annals of hematology, 94(4), 575-581. https://doi.org/10.1007/s00277-014-2240-8

Hasenclever, D., & Diehl, V. (1998). A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. The New England journal of medicine, 339(21), 1506-1514. https://doi.org/10.1056/NEJM199811193392104

Helse- og omsorgsdepartementet. (2006). Nasjonal helseplan (2007-2010) (Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6). Oslo: Helse- og omsorgsdepartementet. Hentet fra http://www.regjeringen.no/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf

Helsedirektoratet. (23. desember 2021). Maligne blodsykdommer - handlingsprogram: nasjonal faglig retningslinje. [nettdokument]. Oslo: Helsedirektoratet. Hentet 17. janaur 2023, fra https://www.helsedirektoratet.no/retningslinjer/maligne-blodsykdommer-handlingsprogram

Helsedirektoratet. (30. desember 2022). Lymfomer: pakkeforløp. [nettdokument]. Oslo: Helsedirektoratet. Hentet 17. januar 2023, fra https://www.helsedirektoratet.no/nasjonale-forlop/lymfomer

Hermine, O., Hoster, E., Walewski, J., Bosly, A., Stilgenbauer, S., Thieblemont, C., . . . European Mantle Cell Lymphoma Network. (2016). Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet, 388(10044), 565-575. https://doi.org/10.1016/S0140-6736(16)00739-X

Herrera, A. F., Mei, M., Low, L., Kim, H. T., Griffin, G. K., Song, J. Y., . . . Armand, P. (2017). Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. Journal of clinical oncology, 35(1), 24-31. https://doi.org/10.1200/JCO.2016.68.2740

Hertzberg, M., Grigg, A., Gottlieb, D., Szer, J., Roberts, A., Hoyt, R., . . . Bradstock, K. F. (2006). Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. Bone marrow transplantation, 37(10), 923-928. https://doi.org/10.1038/sj.bmt.1705357

Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., . . . Unterhalt, M. (2005). Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106(12), 3725-3732. https://doi.org/10.1182/blood-2005-01-0016

Hill, Q. A., & Owen, R. G. (2006). CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood reviews, 20(6), 319-332. https://doi.org/10.1016/j.blre.2006.02.001

Hoelzer, D., Walewski, J., Dohner, H., Viardot, A., Hiddemann, W., Spiekermann, K., . . . German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. (2014). Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood, 124(26), 3870-3879. https://doi.org/10.1182/blood-2014-03-563627

Holland, J. C., & Reznik, I. (2005). Pathways for psychosocial care of cancer survivors. Cancer, 104(11 Suppl), 2624-2637. https://doi.org/10.1002/cncr.21252

Hollender, A., Kvaloy, S., Lote, K., Nome, O., & Holte, H. (2000). Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. European journal of cancer, 36(14), 1762-1768. https://doi.org/10.1016/s0959-8049(00)00171-4

Holte, H., Leppä, S., Björkholm, M., Fluge, O., Jyrkkiö, S., Delabie, J., . . . Eriksson, M. (2013). Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of oncology, 24(5), 1385-1392. https://doi.org/10.1093/annonc/mds621

Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., . . . Trümper, L. (2019). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, 393(10168), 229-240. https://doi.org/10.1016/s0140-6736(18)32984-2

Hoskin, P. J., Diez, P., Williams, M., Lucraft, H., Bayne, M., & Participants of the Lymphoma Radiotherapy, G. (2013). Recommendations for the use of radiotherapy in nodal lymphoma. Clinical oncology (Royal College of Radiologists (Great Britain)), 25(1), 49-58. https://doi.org/10.1016/j.clon.2012.07.011

Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H. C., . . . European Mantle Cell Lymphoma Network. (2008). A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood, 111(2), 558-565. https://doi.org/10.1182/blood-2007-06-095331

Hoster, E., Rosenwald, A., Berger, F., Bernd, H. W., Hartmann, S., Loddenkemper, C., . . . Klapper, W. (2016). Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. Journal of clinical oncology, 34(12), 1386-1394. https://doi.org/10.1200/JCO.2015.63.8387

Hutchings, M., Morschhauser, F., Iacoboni, G., Carlo-Stella, C., Offner, F. C., Sureda, A., . . . Dickinson, M. J. (2021). Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. Journal of clinical oncology, 39(18), 1959-1970. https://doi.org/10.1200/jco.20.03175

Haas, R. L., Poortmans, P., de Jong, D., Aleman, B. M., Dewit, L. G., Verheij, M., . . . Bartelink, H. (2003). High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. Journal of clinical oncology, 21(13), 2474-2480. https://doi.org/10.1200/JCO.2003.09.542

Haas, R. L., Poortmans, P., de Jong, D., Verheij, M., van der Hulst, M., de Boer, J. P., & Bartelink, H. (2005). Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. European journal of cancer, 41(12), 1724-1730. https://doi.org/10.1016/j.ejca.2005.04.033

Illerhaus, G., Ferreri, A. J. M., Binder, M., Borchmann, P., Hasenkamp, J., Stilgenbauer, S., . . . Schorb, E. (2022). LBA-3 Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43). Foredrag på 64th ASH Annual Meeting and Exposition, New Orleans, Louisiana 10.-13. desember 2022. Hentet fra https://ash.confex.com/ash/2022/webprogram/Paper171733.html

Jantunen, E., & Varmavuo, V. (2014). Plerixafor for mobilization of blood stem cells in autologous transplantation: an update. Expert opinion on biological therapy, 14(6), 851-861. https://doi.org/10.1517/14712598.2014.902927

Jerkeman, M., Anderson, H., Cavallin-Stahl, E., Dictor, M., Hagberg, H., Johnson, A., . . . Akerman, M. (1999). CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial. Annals of oncology, 10(9), 1079-1086. https://doi.org/10.1023/a:1008392528248

Jerkeman, M., Leppä, S., Kvaløy, S., & Holte, H. (2004). ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. European journal of haematology, 73(3), 179-182. https://doi.org/10.1111/j.1600-0609.2004.00294.x

Johnson, N. A., Savage, K. J., Ludkovski, O., Ben-Neriah, S., Woods, R., Steidl, C., . . . Horsman, D. E. (2009). Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood, 114(11), 2273-2279. https://doi.org/10.1182/blood-2009-03-212191

Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., . . . Barrington, S. (2016). Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. The New England journal of medicine, 374(25), 2419-2429. https://doi.org/10.1056/NEJMoa1510093

Jones, G. W., Kacinski, B. M., Wilson, L. D., Willemze, R., Spittle, M., Hohenberg, G., . . . Knobler, R. (2002). Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. Journal of the American Academy of Dermatology, 47(3), 364-370. https://doi.org/10.1067/mjd.2002.123482

Juweid, M. E., & Cheson, B. D. (2005). Role of positron emission tomography in lymphoma. Journal of clinical oncology, 23(21), 4577-4580. https://doi.org/10.1200/JCO.2005.01.904

Juweid, M. E., & Cheson, B. D. (2006). Positron-emission tomography and assessment of cancer therapy. The New England journal of medicine, 354(5), 496-507. https://doi.org/10.1056/NEJMra050276

Kahl, B. S., Hong, F., Williams, M. E., Gascoyne, R. D., Wagner, L. I., Krauss, J. C., . . . Horning, S. J. (2014). Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. Journal of clinical oncology, 32(28), 3096-3102. https://doi.org/10.1200/JCO.2014.56.5853

Kamstrup, M. R., Gniadecki, R., Iversen, L., Skov, L., Petersen, P. M., Loft, A., & Specht, L. (2015). Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. International journal of radiation oncology, biology, physics, 92(1), 138-143. https://doi.org/10.1016/j.ijrobp.2015.01.047

Kansara, R., Villa, D., Gerrie, A. S., Klasa, R., Shenkier, T., Scott, D. W., . . . Savage, K. J. (2017). Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. British journal of haematology, 179(3), 508-510. https://doi.org/10.1111/bjh.14229

Kaplan, L. D., Lee, J. Y., Ambinder, R. F., Sparano, J. A., Cesarman, E., Chadburn, A., . . . Scadden, D. T. (2005). Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 106(5), 1538-1543. https://doi.org/10.1182/blood-2005-04-1437

Kasenda, B., Loeffler, J., Illerhaus, G., Ferreri, A. J. M., Rubenstein, J., & Batchelor, T. T. (2016). The role of whole brain radiation in primary CNS lymphoma. Blood, 128(1), 32-36. https://doi.org/10.1182/blood-2016-01-650101

Kasenda, B., Schorb, E., Fritsch, K., Finke, J., & Illerhaus, G. (2012). Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Annals of oncology, 23(10), 2670-2675. https://doi.org/10.1093/annonc/mds059

Khouri, I. F., Lee, M. S., Saliba, R. M., Jun, G., Fayad, L., Younes, A., . . . Champlin, R. E. (2003). Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. Journal of clinical oncology, 21(23), 4407-4412. https://doi.org/10.1200/JCO.2003.05.501

Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., . . . Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of clinical oncology, 33(32), 3750-3758. https://doi.org/10.1200/JCO.2014.60.3969

Kimby, E., Ostenstad, B., Brown, P., Hagberg, H., Erlanson, M., Holte, H., . . . Nordic Lymphoma Group. (2015). Two courses of four weekly infusions of rituximab with or without interferon-alpha2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leukemia & lymphoma, 56(9), 2598-2607. https://doi.org/10.3109/10428194.2015.1014363

Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., . . . Dreyling, M. H. (2012). Treatment of older patients with mantle-cell lymphoma. The New England journal of medicine, 367(6), 520-531. https://doi.org/10.1056/NEJMoa1200920

Knols, R., Aaronson, N. K., Uebelhart, D., Fransen, J., & Aufdemkampe, G. (2005). Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. Journal of clinical oncology, 23(16), 3830-3842. https://doi.org/10.1200/JCO.2005.02.148

Koch, P., Grothaus-Pinke, B., Hiddemann, W., Willich, N., Reers, B., del Valle, F., . . . Tiemann, M. (1997). Primary lymphoma of the stomach: three-year results of a prospective multicenter study. The German Multicenter Study Group on GI-NHL. Annals of oncology, 8(Suppl 1), 85-88.

Kolstad, A., Holte, H., Fosså, A., Lauritzsen, G. F., Gaustad, P., & Torfoss, D. (2007a). Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica, 92(1), 139-140. https://doi.org/10.3324/haematol.10564

Kolstad, A., Laurell, A., Jerkeman, M., Gronbaek, K., Elonen, E., Raty, R., . . . Nordic Lymphoma Group. (2014). Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood, 123(19), 2953-2959. https://doi.org/10.1182/blood-2013-12-541953

Kolstad, A., Nome, O., Delabie, J., Lauritzsen, G. F., Fossa, A., & Holte, H. (2007b). Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leukemia & lymphoma, 48(3), 570-576. https://doi.org/10.1080/10428190601126610

Korfel, A., Thiel, E., Martus, P., Mohle, R., Griesinger, F., Rauch, M., . . . Weller, M. (2015). Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology, 84(12), 1242-1248. https://doi.org/10.1212/WNL.0000000000001395

Kristinsson, S. Y., Goldin, L. R., Björkholm, M., Koshiol, J., Turesson, I., & Landgren, O. (2009). Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica, 94(11), 1581-1589. https://doi.org/10.3324/haematol.2009.008979

Kusumi, E., Kami, M., Kanda, Y., Murashige, N., Kishi, Y., Suzuki, R., . . . Takaue, Y. (2005). Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone marrow transplantation, 36(3), 205-213. https://doi.org/10.1038/sj.bmt.1705027

Kwong, Y. L., Kim, W. S., Lim, S. T., Kim, S. J., Tang, T., Tse, E., . . . Chim, C. S. (2012). SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood, 120(15), 2973-2980. https://doi.org/10.1182/blood-2012-05-431460

Lagerlöf, I., Holte, H., Glimelius, I., Björkholm, M., Enblad, G., Erlanson, M., . . . Molin, D. (2020). No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British journal of haematology, 188(5), 685-691. https://doi.org/10.1111/bjh.16232

Lambertini, M., Peccatori, F. A., Demeestere, I., Amant, F., Wyns, C., Stukenborg, J. B., . . . Jordan, K. (2020). Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines(†). Annals of oncology, 31(12), 1664-1678. https://doi.org/10.1016/j.annonc.2020.09.006

Larsen, I. K. (red.). (2022). Cancer in Norway 2021: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. Hentet fra https://www.kreftregisteret.no/globalassets/cancer-in-norway/2021/cin_report.pdf

Le Gouill, S., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Dartigeas, C., . . . Lysa Group. (2017). Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. The New England journal of medicine, 377(13), 1250-1260. https://doi.org/10.1056/NEJMoa1701769

Lekovich, J., Lobel, A. L. S., Stewart, J. D., Pereira, N., Kligman, I., & Rosenwaks, Z. (2016). Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies. Journal of assisted reproduction and genetics, 33(5), 657-662. https://doi.org/10.1007/s10815-016-0689-1

Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner, B., . . . Hiddemann, W. (2005). Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Journal of clinical oncology, 23(9), 1984-1992. https://doi.org/10.1200/JCO.2005.08.133

Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., . . . Gribben, J. G. (2019). AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. Journal of clinical oncology, 37(14), 1188-1199. https://doi.org/10.1200/jco.19.00010

Leppa, S., Jørgensen, J. M., Karjalainen-Lindsberg, M.-L., Beiske, K., Pedersen, M., Drott, K., . . . Holte, H. (2022). Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study. Blood, 140(Suppl 1), 1768-1769. https://doi.org/10.1182/blood-2022-158183

Leppä, S., Jørgensen, J., Tierens, A., Meriranta, L., Østlie, I., de Nully Brown, P., . . . Holte, H. (2020). Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood advances, 4(9), 1906-1915. https://doi.org/10.1182/bloodadvances.2020001518

Levernes, S., & Johannessen, D. C. (2003). Volum og doser ved strålebehandling: definisjoner, retningslinjer for bruk, dokumentasjon og rapportering (StrålevernRapport 2003:12). Østerås: Statens strålevern. Hentet fra https://dsa.no/publikasjoner/stralevernrapport-12-2003-volum-og-doser-ved-stralebehandling/straalevernrapport-2003-12-volum-og-doser-ved-straalebehandling-definisjoner-retningslinjer-dokumentasjon-rapportering.pdf

Lin, T. L., Kuo, M. C., Shih, L. Y., Dunn, P., Wang, P. N., Wu, J. H., . . . Lu, S. C. (2012). Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. Annals of hematology, 91(11), 1741-1745. https://doi.org/10.1007/s00277-012-1508-0

Linch, D. C., Winfield, D., Goldstone, A. H., Moir, D., Hancock, B., McMillan, A., . . . Hudson, G. V. (1993). Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet, 341(8852), 1051-1054. https://doi.org/10.1016/0140-6736(93)92411-l

Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P., Young, R. C., . . . Tubiana, M. (1989). Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. Journal of clinical oncology, 7(11), 1630-1636. https://doi.org/10.1200/JCO.1989.7.11.1630

Liu, H., Ye, H., Ruskone-Fourmestraux, A., De Jong, D., Pileri, S., Thiede, C., . . . Du, M. Q. (2002). T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology, 122(5), 1286-1294. https://doi.org/10.1053/gast.2002.33047

Ljungman, P., Cordonnier, C., Einsele, H., Englund, J., Machado, C. M., Storek, J., & Small, T. (2009). Vaccination of hematopoietic cell transplant recipients. Bone marrow transplantation, 44(8), 521-526. https://doi.org/10.1038/bmt.2009.263

Lofthus, A. S., & Allen, S. M. (2006). Kan transkutan elektrisk nervestimulering lindre nevropatisk smerte? Fysioterapeuten, 73(4), 16-25.

Loge, J. H., Abrahamsen, A. F., Ekeberg, O., & Kaasa, S. (1999). Hodgkin's disease survivors more fatigued than the general population. Journal of clinical oncology, 17(1), 253-261. https://doi.org/10.1200/JCO.1999.17.1.253

Lok, A. S. F., & Bonis, P. A. L. (18. desember 2017). Hepatitis B virus reactivation associated with immunosuppressive therapy. [database]. Waltham, MA: UpToDate, Inc. Hentet 10. desember 2018

Lote, K., Holte, H., Nome, O., Langholm, R., & Kvaløy, S. (2000). Stage I high-grade non-Hodgkin's lymphoma. Acta oncologica, 39(7), 865-872. https://doi.org/10.1080/028418600750063631

Lowry, L., Smith, P., Qian, W., Falk, S., Benstead, K., Illidge, T., . . . Hoskin, P. (2011). Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiotherapy and oncology, 100(1), 86-92. https://doi.org/10.1016/j.radonc.2011.05.013

Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., . . . Hiddemann, W. (2017). Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. The New England journal of medicine, 377(14), 1331-1344. https://doi.org/10.1056/NEJMoa1614598

Maris, M. B., Sandmaier, B. M., Storer, B. E., Chauncey, T., Stuart, M. J., Maziarz, R. T., . . . Maloney, D. G. (2004). Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood, 104(12), 3535-3542. https://doi.org/10.1182/blood-2004-06-2275

Martelli, M., Ferreri, A. J., & Johnson, P. (2008). Primary mediastinal large B-cell lymphoma. Critical reviews in oncology/hematology, 68(3), 256-263. https://doi.org/10.1016/j.critrevonc.2008.07.020

Martinelli, G., Schmitz, S. F., Utiger, U., Cerny, T., Hess, U., Bassi, S., . . . Ghielmini, M. (2010). Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. Journal of clinical oncology, 28(29), 4480-4484. https://doi.org/10.1200/JCO.2010.28.4786

Mauch, P. (2001). Follicular non-Hodgkin's lymphoma: the role of radiation therapy. Annals of hematology, 80(Suppl 3), B63-65. https://doi.org/10.1007/pl00022793

Mauz-Körholz, C., Landman-Parker, J., Balwierz, W., Ammann, R. A., Anderson, R. A., Attarbaschi, A., . . . Wallace, W. H. (2022). Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. The Lancet. Oncology, 23(1), 125-137. https://doi.org/10.1016/s1470-2045(21)00470-8

Mehra, T., Ikenberg, K., Moos, R. M., Benz, R., Nair, G., Schanz, U., . . . Cozzio, A. (2015). Brentuximab as a treatment for CD30+ mycosis fungoides and Sezary syndrome. JAMA dermatology, 151(1), 73-77. https://doi.org/10.1001/jamadermatol.2014.1629

Meissner, J., Tichy, D., Dietrich, S., Schmitt, T., Ziepert, M., Kuhnt, E., . . . Ho, A. D. (2014). Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma. British journal of haematology, 166(4), 612-615. https://doi.org/10.1111/bjh.12877

Meissner, J., Tichy, D., Katzke, V., Kühn, T., Dietrich, S., Schmitt, T., . . . Ho, A. D. (2015). Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma. Annals of oncology, 26(8), 1771-1776. https://doi.org/10.1093/annonc/mdv227

Melchers, R. C., Willemze, R., Daniëls, L. A., Neelis, K. J., Bekkenk, M. W., de Haas, E. R. M., . . . Quint, K. D. (2017). Recommendations for the Optimal Radiation Dose in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma: A Report of the Dutch Cutaneous Lymphoma Group. International journal of radiation oncology, biology, physics, 99(5), 1279-1285. https://doi.org/10.1016/j.ijrobp.2017.08.010

Melsack, R., & Wall, P. D. E. (red.). (1999). Textbook of pain (4. utg.). Edinburgh: Churchill Livingstone.

Mirza, M. R., & Brincker, H. (1991). MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study. Acta oncologica, 30(1), 17-21. https://doi.org/10.3109/02841869109091807

Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., . . . Mackinnon, S. (2004). Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104(13), 3865-3871. https://doi.org/10.1182/blood-2004-03-1105

Morris, P. G., Correa, D. D., Yahalom, J., Raizer, J. J., Schiff, D., Grant, B., . . . Omuro, A. (2013). Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. Journal of clinical oncology, 31(31), 3971-3979. https://doi.org/10.1200/JCO.2013.50.4910

Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., . . . Salles, G. A. (2018). Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. The New England journal of medicine, 379(10), 934-947. https://doi.org/10.1056/NEJMoa1805104

Moskowitz, A. J., Lunning, M. A., & Horwitz, S. M. (2014). How I treat the peripheral T-cell lymphomas. Blood, 123(17), 2636-2644. https://doi.org/10.1182/blood-2013-12-516245

Moskowitz, C. H., Bertino, J. R., Glassman, J. R., Hedrick, E. E., Hunte, S., Coady-Lyons, N., . . . Zelenetz, A. D. (1999). Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. Journal of clinical oncology, 17(12), 3776-3785. https://doi.org/10.1200/JCO.1999.17.12.3776

Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., . . . Aethera Study Group. (2015). Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 385(9980), 1853-1862. https://doi.org/10.1016/S0140-6736(15)60165-9

Mounier, N., Spina, M., Gabarre, J., Raphael, M., Rizzardini, G., Golfier, J. B., . . . Gisselbrecht, C. (2006). AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood, 107(10), 3832-3840. https://doi.org/10.1182/blood-2005-09-3600

Nakamura, S., Ye, H., Bacon, C. M., Goatly, A., Liu, H., Banham, A. H., . . . Du, M. Q. (2007). Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation. Gut, 56(10), 1358-1363. https://doi.org/10.1136/gut.2007.123729

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., . . . Go, W. Y. (2017). Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England journal of medicine, 377(26), 2531-2544. https://doi.org/10.1056/NEJMoa1707447

Ohkubo, Y., Saito, Y., Ushijima, H., Onishi, M., Kazumoto, T., Saitoh, J. I., . . . Kurosumi, M. (2017). Radiotherapy for localized gastric mucosa-associated lymphoid tissue lymphoma: long-term outcomes over 10 years. Journal of radiation research, 58(4), 537-542. https://doi.org/10.1093/jrr/rrw044

Oktay, K., Harvey, B. E., Partridge, A. H., Quinn, G. P., Reinecke, J., Taylor, H. S., . . . Loren, A. W. (2018). Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of clinical oncology, 36(19), 1994-2001. https://doi.org/10.1200/jco.2018.78.1914

Omuro, A., Correa, D. D., DeAngelis, L. M., Moskowitz, C. H., Matasar, M. J., Kaley, T. J., . . . Sauter, C. S. (2015). R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood, 125(9), 1403-1410. https://doi.org/10.1182/blood-2014-10-604561

Omuro, A. M. P., DeAngelis, L. M., Karrison, T., Bovi, J. A., Rosenblum, M., Corn, B. W., . . . NRG. (2020). Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). Journal of clinical oncology, 38(15_suppl), 2501-2501. https://doi.org/10.1200/JCO.2020.38.15_suppl.2501

Oslo universitetssykehus HF. (15. september 2022). Nasjonal behandlingstjeneste for fertilitetsbevarende behandling med eggstokkvev. [nettdokument]. Oslo: Oslo universitetssykehus HF. Hentet 17. januar 2023, fra https://oslo-universitetssykehus.no/fag-og-forskning/nasjonale-og-regionale-tjenester/nasjonal-behandlingstjeneste-for-fertilitetsbevarende-behandling-med-autologt-ovarialvev

Ozsahin, M., Tsang, R. W., Poortmans, P., Belkacémi, Y., Bolla, M., Dincbas, F. O., . . . Zouhair, A. (2006). Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. International journal of radiation oncology, biology, physics, 64(1), 210-217. https://doi.org/10.1016/j.ijrobp.2005.06.039

Peyrade, F., Jardin, F., Thieblemont, C., Thyss, A., Emile, J. F., Castaigne, S., . . . Groupe d'Etude des Lymphomes de l'Adulte investigators. (2011). Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet. Oncology, 12(5), 460-468. https://doi.org/10.1016/S1470-2045(11)70069-9

Pfreundschuh, M. (2005). Mature T-cell and NK/T-cell neoplasms. Clinical advances in hematology & oncology : H&O, 3(11), suppl 8-9.

Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., . . . German High-Grade Non-Hodgkin Lymphoma Study Group. (2008). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet. Oncology, 9(2), 105-116. https://doi.org/10.1016/S1470-2045(08)70002-0

Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A. C., Rube, C., . . . German High-Grade Non-Hodgkin's Lymphoma Study Group. (2004a). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood, 104(3), 634-641. https://doi.org/10.1182/blood-2003-06-2095

Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A. C., Rudolph, C., . . . German High-Grade Non-Hodgkin's Lymphoma Study Group. (2004b). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood, 104(3), 626-633. https://doi.org/10.1182/blood-2003-06-2094

Pfreundschuh, M., Trümper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., . . . MabThera International Trial Group. (2006). CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet. Oncology, 7(5), 379-391. https://doi.org/10.1016/S1470-2045(06)70664-7

Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., . . . Chauvin, F. (1995). Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. The New England journal of medicine, 333(23), 1540-1545. https://doi.org/10.1056/NEJM199512073332305

Poeschel, V., Held, G., Ziepert, M., Witzens-Harig, M., Holte, H., Thurner, L., . . . German Lymphoma Alliance. (2020). Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet, 394(10216), 2271-2281. https://doi.org/10.1016/S0140-6736(19)33008-9

Prince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., . . . Alcanza study group. (2017). Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, 390(10094), 555-566. https://doi.org/10.1016/S0140-6736(17)31266-7

Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., . . . Shustov, A. (2012). Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. Journal of clinical oncology, 30(18), 2190-2196. https://doi.org/10.1200/JCO.2011.38.0402

Pulczynski, E. J., Kuittinen, O., Erlanson, M., Hagberg, H., Fosså, A., Eriksson, M., . . . Fagerli, U. M. (2015). Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica, 100(4), 534-540. https://doi.org/10.3324/haematol.2014.108472

Quasthoff, S., & Hartung, H. P. (2002). Chemotherapy-induced peripheral neuropathy. Journal of neurology, 249(1), 9-17. https://doi.org/10.1007/pl00007853

Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grunhagen, U., Losem, C., . . . Study group indolent Lymphomas. (2013). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet, 381(9873), 1203-1210. https://doi.org/10.1016/S0140-6736(12)61763-2

Salles, G., Duell, J., González Barca, E., Tournilhac, O., Jurczak, W., Liberati, A. M., . . . Maddocks, K. (2020). Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. The Lancet. Oncology, 21(7), 978-988. https://doi.org/10.1016/S1470-2045(20)30225-4

Salles, G., Seymour, J. F., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., . . . Tilly, H. (2011). Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, 377(9759), 42-51. https://doi.org/10.1016/S0140-6736(10)62175-7

Sankila, R., Garwicz, S., Olsen, J. H., Dollner, H., Hertz, H., Kreuger, A., . . . Tulinius, H. (1996). Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. Journal of clinical oncology, 14(5), 1442-1446. https://doi.org/10.1200/JCO.1996.14.5.1442

Santoro, A., Magagnoli, M., Spina, M., Pinotti, G., Siracusano, L., Michieli, M., . . . Balzarotti, M. (2007). Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica, 92(1), 35-41. https://doi.org/10.3324/haematol.10661

Savage, K. J., Johnson, N. A., Ben-Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P., . . . Gascoyne, R. D. (2009). MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood, 114(17), 3533-3537. https://doi.org/10.1182/blood-2009-05-220095

Savage, K. J., Skinnider, B., Al-Mansour, M., Sehn, L. H., Gascoyne, R. D., & Connors, J. M. (2011). Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood, 118(17), 4585-4590. https://doi.org/10.1182/blood-2011-07-365932

Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M., Haenel, M., . . . Marrow, T. (2002). Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 359(9323), 2065-2071. https://doi.org/10.1016/S0140-6736(02)08938-9

Schmitz, N., Zeynalova, S., Nickelsen, M., Kansara, R., Villa, D., Sehn, L. H., . . . Savage, K. J. (2016). CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of clinical oncology, 34(26), 3150-3156. https://doi.org/10.1200/JCO.2015.65.6520

Schouten, H. C., Qian, W., Kvaloy, S., Porcellini, A., Hagberg, H., Johnsen, H. E., . . . Kvalheim, G. (2003). High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. Journal of clinical oncology, 21(21), 3918-3927. https://doi.org/10.1200/JCO.2003.10.023

Schulz, H., Rehwald, U., Morschhauser, F., Elter, T., Driessen, C., Rudiger, T., . . . Reiser, M. (2008). Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood, 111(1), 109-111. https://doi.org/10.1182/blood-2007-03-078725

Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., . . . Maziarz, R. T. (2018). Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The New England journal of medicine, 380(1), 45-56. https://doi.org/10.1056/NEJMoa1804980

Schüring, A. N., Fehm, T., Behringer, K., Goeckenjan, M., Wimberger, P., Henes, M., . . . von Wolff, M. (2018). Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation. Archives of gynecology and obstetrics, 297(1), 241-255. https://doi.org/10.1007/s00404-017-4594-3

Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., . . . Connors, J. M. (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109(5), 1857-1861. https://doi.org/10.1182/blood-2006-08-038257

Sehn, L. H., Chua, N., Mayer, J., Dueck, G., Trneny, M., Bouabdallah, K., . . . Cheson, B. D. (2016). Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. The Lancet. Oncology, 17(8), 1081-1093. https://doi.org/10.1016/S1470-2045(16)30097-3

Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., . . . Matasar, M. J. (2020). Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of clinical oncology, 38(2), 155-165. https://doi.org/10.1200/JCO.19.00172

Sesques, P., & Johnson, N. A. (2017). Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood, 129(3), 280-288. https://doi.org/10.1182/blood-2016-02-636316

Shah, G. D., Yahalom, J., Correa, D. D., Lai, R. K., Raizer, J. J., Schiff, D., . . . Abrey, L. E. (2007). Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. Journal of clinical oncology, 25(30), 4730-4735. https://doi.org/10.1200/JCO.2007.12.5062

Smeland, S., Blystad, A. K., Kvaløy, S. O., Ikonomou, I. M., Delabie, J., Kvalheim, G., . . . Holte, H. (2004). Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Annals of oncology, 15(7), 1072-1078. https://doi.org/10.1093/annonc/mdh262

Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J. O., Arranz-Saez, R., . . . Montserrat, E. (2004). Follicular lymphoma international prognostic index. Blood, 104(5), 1258-1265. https://doi.org/10.1182/blood-2003-12-4434

Soutar, R., Lucraft, H., Jackson, G., Reece, A., Bird, J., Low, E., . . . British Society for Haematology. (2004). Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. British journal of haematology, 124(6), 717-726. https://doi.org/10.1111/j.1365-2141.2004.04834.x

Sparano, J. A. (2007). HIV-associated lymphoma: the evidence for treating aggressively but with caution. Current opinion in oncology, 19(5), 458-463. https://doi.org/10.1097/CCO.0b013e3282c8c835

Specht, L., Dabaja, B., Illidge, T., Wilson, L. D., & Hoppe, R. T. (2015). Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. International journal of radiation oncology, biology, physics, 92(1), 32-39. https://doi.org/10.1016/j.ijrobp.2015.01.008

Stein, H., Foss, H. D., Durkop, H., Marafioti, T., Delsol, G., Pulford, K., . . . Falini, B. (2000). CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood, 96(12), 3681-3695.

Suarez, F., Lortholary, O., Hermine, O., & Lecuit, M. (2006). Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood, 107(8), 3034-3044. https://doi.org/10.1182/blood-2005-09-3679

Sureda, A., Robinson, S., Canals, C., Carella, A. M., Boogaerts, M. A., Caballero, D., . . . Schmitz, N. (2008). Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of clinical oncology, 26(3), 455-462. https://doi.org/10.1200/JCO.2007.13.2415

Sweetenham, J. W., Santini, G., Qian, W., Guelfi, M., Schmitz, N., Simnett, S., . . . Goldstone, A. H. (2001). High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. Journal of clinical oncology, 19(11), 2927-2936. https://doi.org/10.1200/JCO.2001.19.11.2927

Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., & Thiele, J. (red.). (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4. rev. utg.). (WHO Classification of Tumours, Volume 2). Lyon: IARC.

Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., . . . Jaffe, E. S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20), 2375-2390. https://doi.org/10.1182/blood-2016-01-643569

Thieblemont, C., & Coiffier, B. (2006). Management of marginal zone lymphomas. Current treatment options in oncology, 7(3), 213-222. https://doi.org/10.1007/s11864-006-0014-9

Thieblemont, C., & Zucca, E. (2017). Clinical aspects and therapy of gastrointestinal MALT lymphoma. Best practice & research. Clinical haematology, 30(1-2), 109-117. https://doi.org/10.1016/j.beha.2017.01.002

Trautinger, F., Knobler, R., Willemze, R., Peris, K., Stadler, R., Laroche, L., . . . Whittaker, S. (2006). EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. European journal of cancer, 42(8), 1014-1030. https://doi.org/10.1016/j.ejca.2006.01.025

Tsai, H. K., & Mauch, P. M. (2007). Nodular lymphocyte-predominant hodgkin lymphoma. Seminars in radiation oncology, 17(3), 184-189. https://doi.org/10.1016/j.semradonc.2007.02.004

Tsang, R. W., Campbell, B. A., Goda, J. S., Kelsey, C. R., Kirova, Y. M., Parikh, R. R., . . . Yahalom, J. (2018). Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. International journal of radiation oncology, biology, physics, 101(4), 794-808. https://doi.org/10.1016/j.ijrobp.2018.05.009

Tsang, R. W., & Gospodarowicz, M. K. (2007). Low-grade non-hodgkin lymphomas. Seminars in radiation oncology, 17(3), 198-205. https://doi.org/10.1016/j.semradonc.2007.02.006

Tsimberidou, A. M., Catovsky, D., Schlette, E., O'Brien, S., Wierda, W. G., Kantarjian, H., . . . Keating, M. J. (2006). Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer, 107(1), 125-135. https://doi.org/10.1002/cncr.21931

Van Besien, K. (2006). The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood reviews, 20(5), 235-244. https://doi.org/10.1016/j.blre.2006.01.001

van Oers, M. H., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., . . . Hagenbeek, A. (2006). Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 108(10), 3295-3301. https://doi.org/10.1182/blood-2006-05-021113

van Oers, M. H., Van Glabbeke, M., Giurgea, L., Klasa, R., Marcus, R. E., Wolf, M., . . . Hagenbeek, A. (2010). Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. Journal of clinical oncology, 28(17), 2853-2858. https://doi.org/10.1200/JCO.2009.26.5827

Vidal, L., Gafter-Gvili, A., Salles, G., Dreyling, M. H., Ghielmini, M., Hsu Schmitz, S. F., . . . Shpilberg, O. (2011). Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. Journal of the National Cancer Institute, 103(23), 1799-1806. https://doi.org/10.1093/jnci/djr418

Voong, K. R., McSpadden, K., Pinnix, C. C., Shihadeh, F., Reed, V., Salehpour, M. R., . . . Dabaja, B. S. (2014). Dosimetric advantages of a "butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma. Radiation oncology (London, England), 9, 94. https://doi.org/10.1186/1748-717x-9-94

Voss, M. H., Lunning, M. A., Maragulia, J. C., Papadopoulos, E. B., Goldberg, J., Zelenetz, A. D., & Horwitz, S. M. (2013). Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clinical lymphoma, myeloma & leukemia, 13(1), 8-14. https://doi.org/10.1016/j.clml.2012.09.002

Wang, M. L., Lee, H., Chuang, H., Wagner-Bartak, N., Hagemeister, F., Westin, J., . . . Zhang, L. (2016). Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. The Lancet. Oncology, 17(1), 48-56. https://doi.org/10.1016/S1470-2045(15)00438-6

Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., . . . Blum, K. A. (2013). Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. The New England journal of medicine, 369(6), 507-516. https://doi.org/10.1056/NEJMoa1306220

Wasterlid, T., Hartman, L., Szekely, E., & Jerkeman, M. (2017). Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Hematological oncology, 35(2), 151-157. https://doi.org/10.1002/hon.2256

Weisenburger, D. D., & Armitage, J. O. (1996). Mantle cell lymphoma-- an entity comes of age. Blood, 87(11), 4483-4494.

Wilkosz, P., Greggains, G. D., Tanbo, T. G., & Fedorcsak, P. (2014). Female reproductive decline is determined by remaining ovarian reserve and age. PLoS One, 9(10), e108343. https://doi.org/10.1371/journal.pone.0108343

Willemze, R., Cerroni, L., Kempf, W., Berti, E., Facchetti, F., Swerdlow, S. H., & Jaffe, E. S. (2019). The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood, 133(16), 1703-1714. https://doi.org/10.1182/blood-2018-11-881268

Willemze, R., Jaffe, E. S., Burg, G., Cerroni, L., Berti, E., Swerdlow, S. H., . . . Meijer, C. J. (2005). WHO-EORTC classification for cutaneous lymphomas. Blood, 105(10), 3768-3785. https://doi.org/10.1182/blood-2004-09-3502

Willemze, R., & Meijer, C. J. (2003). Primary cutaneous CD30-positive lymphoproliferative disorders. Hematology/oncology clinics of North America, 17(6), 1319-1332, vii-viii. https://doi.org/10.1016/s0889-8588(03)00117-5

Wilson, M. R., Eyre, T. A., Kirkwood, A. A., Wong Doo, N., Soussain, C., Choquet, S., . . . McKay, P. (2022). Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood, 139(16), 2499-2511. https://doi.org/10.1182/blood.2021014506

Wilson, W. H., Grossbard, M. L., Pittaluga, S., Cole, D., Pearson, D., Drbohlav, N., . . . Balis, F. (2002). Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood, 99(8), 2685-2693. https://doi.org/10.1182/blood.v99.8.2685

Wirth, A., Mikhaeel, N. G., Aleman, B. M. P., Pinnix, C. C., Constine, L. S., Ricardi, U., . . . Specht, L. (2020). Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. International journal of radiation oncology, biology, physics, 107(5), 909-933. https://doi.org/10.1016/j.ijrobp.2020.03.019

Wittink, H., & Michel, T. H. (red.). (2002). Chronic pain management for physical therapists (2. utg.). Woburn, MA: Elsevier Science.

Wong, J. Y. C., Filippi, A. R., Dabaja, B. S., Yahalom, J., & Specht, L. (2018). Total Body Irradiation: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). International journal of radiation oncology, biology, physics, 101(3), 521-529. https://doi.org/10.1016/j.ijrobp.2018.04.071

Wotherspoon, A. C., Doglioni, C., Diss, T. C., Pan, L., Moschini, A., de Boni, M., & Isaacson, P. G. (1993). Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 342(8871), 575-577. https://doi.org/10.1016/0140-6736(93)91409-f

Wundisch, T., Thiede, C., Morgner, A., Dempfle, A., Gunther, A., Liu, H., . . . Neubauer, A. (2005). Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. Journal of clinical oncology, 23(31), 8018-8024. https://doi.org/10.1200/JCO.2005.02.3903

Yahalom, J., Illidge, T., Specht, L., Hoppe, R. T., Li, Y.-X., Tsang, R., & Wirth, A. (2015). Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International journal of radiation oncology, biology, physics, 92(1), 11-31. https://doi.org/10.1016/j.ijrobp.2015.01.009

Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., . . . Chen, R. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of clinical oncology, 30(18), 2183-2189. https://doi.org/10.1200/JCO.2011.38.0410

Yuen, A. R., Rosenberg, S. A., Hoppe, R. T., Halpern, J. D., & Horning, S. J. (1997). Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood, 89(3), 814-822.

Zaorsky, N. G., Williams, G. R., Barta, S. K., Esnaola, N. F., Kropf, P. L., Hayes, S. B., & Meyer, J. E. (2017). Splenic irradiation for splenomegaly: A systematic review. Cancer treatment reviews, 53, 47-52. https://doi.org/10.1016/j.ctrv.2016.11.016

Zhang, N., Xu, D., Liu, B., Shi, X., Xie, X., & Wang, Z. (2022). Prophylaxis strategies containing high dose intravenous methotrexate on preventing CNS relapse for patients with diffuse large B-cell lymphoma at intermediate to high risk: A study based on 12 cohorts in the rituximab era. International immunopharmacology, 113(Pt A), 109299. https://doi.org/10.1016/j.intimp.2022.109299

Zhou, Z., Sehn, L. H., Rademaker, A. W., Gordon, L. I., Lacasce, A. S., Crosby-Thompson, A., . . . Winter, J. N. (2014). An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 123(6), 837-842. https://doi.org/10.1182/blood-2013-09-524108

Zucca, E., Conconi, A., Laszlo, D., Lopez-Guillermo, A., Bouabdallah, R., Coiffier, B., . . . Thieblemont, C. (2013). Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. Journal of clinical oncology, 31(5), 565-572. https://doi.org/10.1200/JCO.2011.40.6272

Zucca, E., Roggero, E., Bertoni, F., Conconi, A., & Cavalli, F. (1999). Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Annals of oncology, 10(9), 1023-1033. https://doi.org/10.1023/a:1008313229892

Zucca, E., Rondeau, S., Vanazzi, A., Østenstad, B., Mey, U. J. M., Rauch, D., . . . the Nordic Lymphoma Group. (2019). Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood, 134(4), 353-362. https://doi.org/10.1182/blood-2018-10-879643